Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Will the new wave of “generic” biologics help curb soaring drug prices?
May 5, 2016
By: Tim Wright
Editor-in-Chief, Contract Pharma
Drug pricing is one of the hot topics in the 2016 U.S. presidential campaign and the burden of high drug costs not just to patients but to the entire healthcare system may be the one thing both Republican and Democrats actually agree on that needs fixing. At the same time that drug prices have soared over the past decade, the growth of biologics, which include many of the specialty, high-cost drugs used today to treat chronic diseases like cancer and diabetes, has been a dominant theme in the pharmaceutical industry. On average, biologic drugs are about 20 times more expensive than traditional drugs, and it is expected that biologics will account for roughly 50% of U.S. prescription drug expenditures by 2018. IMS Health data says global biologic sales increased from about $45 billion in 2002 to $160 billion in 2012 with expected sales in 2017 of $221 billion—20% of total global pharmaceuticals sales. However, with the emergence of biosimilars on the scene representing a new wave of drugs, these “generic” versions of expensive branded specialty biologic drugs may be part of a solution to bring overall drug costs down and help alleviate the pressure on the U.S. healthcare system. In an article he penned for Inside Sources, Amit Munshi, the president and chief executive officer of Epirus Biopharmaceuticals, a Boston company focused on the global development and commercialization of biosimilar monoclonal antibodies, said the rising use of biologic drugs in the U.S. more so than in other parts of the world and, lack of approved biosimilars, are key contributing factors to escalating drug prices. He said: “According to ExpressScripts, only about 2 percent of the population takes biologic drugs. Yet, the cost of biologic drugs accounts for roughly 40 percent of total prescription drug spending in the United States. The obvious challenge is how to slow this freight train without derailing the incentives to innovate that have nourished the biologics revolution.” Global sales of biosimilar drugs are expected to rise from $2.5 billion in 2014 to $26.5 billion by 2020. According to various estimates, healthcare savings from the use of biosimilars range from $25 billion to $250 billion over the period 2014-2024. Biosimilars market projections predict that 50% of the biologics market will belong to off-patent drugs, creating a huge market potential. With the election year in full swing and candidates on both sides of the fence publicly demanding lower drug prices, can biosimilars help carve a path towards achieving that goal? Tim Wright, Editor twright@rodmanmedia.com
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !